# Kentucky Cancer Registry DIAGNOSTIC CONFIRMATION CODE

NAACCR Data Item #490

# **Diagnostic Confirmation Code**



### STORE MANUAL: PAGES 142 – 144

KENTUCKY CANCER REGISTRY ABSTRACTOR'S MANUAL: PAGES 138-140

# Description

Records the **best** method of diagnostic confirmation of the cancer being reported **at any time** in the patient's history.

## **IMPORTANT:**

The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.

# Rationale

This item is an indicator of the precision of diagnosis.

The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases.

# **Coding Instructions**

The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.

Two separate flow charts have been created



Solid Tumor (all tumors <u>except</u> M9590 – 9992)



Hematopoietic or Lymphoid Tumors (M9590-9992)

# Solid Tumor (All tumors <u>except</u> M9590 – <u>9992</u>)

# Solid Tumor (All tumors <u>except</u> M9590 – 9992)

- These instructions apply to "Codes for Solid Tumors" **only**.
- The codes are in priority hierarchy order.
- Code 1 has the highest priority.
- When the presence of cancer is confirmed with multiple diagnostic methods, code the <u>most definitive</u> method used, if it is uncertain, code the procedure with the lower numeric value
- This data item <u>must be changed</u> to the lower (higher priority) code if a more definitive method confirms the diagnosis <u>at any</u> <u>time during the course of the disease.</u>

# Code 1 Positive Histology

Code 1 has the highest priority

Assign code 1:

When the *microscopic* diagnosis is based on tissue specimens from:

- Biopsy
- Frozen section
- Surgery
- Autopsy
- D&C
- Bone marrow biopsy/aspiration

# Code 2 Positive Cytology

#### Assign code 2:

When the *microscopic* diagnosis is based on cytologic examination of cells such as:

- Sputum smears
- Bronchial brushings
- Bronchial washings
- Prostatic secretions
- Breast secretions
- Gastric fluid
- Spinal fluid

- Peritoneal fluid
- Pleural fluid
- Urinary sediment
- Cervical smears
- Vaginal smears
- Paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.

**IMPORTANT**: CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.

# Code 4 Positive microscopic confirmation, NOS

## Assign code 4:

Microscopic confirmation is all that is known.

• It is unknown if the cells were from histology or cytology.

#### **Example:**

The only information that you have is a report that states a pathology result but does not give the type of method or sample used and there are no op or procedure notes.

# Code 5 Positive Laboratory/Marker Tests

### Assign code 5:

• When the diagnosis of cancer is based on positive laboratory tests or marker studies which are clinically diagnostic for that specific cancer.

### Examples include, but not limited to:

- AFP for liver cancer
- Elevated PSA (Note: An elevated PSA is only diagnostic of cancer if the physician uses the PSA as a basis for diagnosing prostate cancer with no further workup.)

# Code 6 Direct Visualization <u>without</u> Microscopic Confirmation

#### Assign code 6:

- When there is direct visualization without microscopic confirmation.
- The tumor was visualized during a surgical or endoscopic procedure with no tissue resected for microscopic examination.
- Use this code when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy, or from gross autopsy findings in the absence of tissue or cytology findings.

#### **Example**:

Ablation of a tumor. Tumor was seen by the physician during an ablation surgery, the tumor was destroyed and no tissue was sent to pathology.

# Code 7 Imaging Techniques <u>without</u> Microscopic Confirmation

### Assign Code 7:

The malignancy was reported by the physician from an imaging technique report only.

### **Example:**

Scan of the liver revealed a tumor consistent with cholangiocarcinoma (CC). Lab tests are inconclusive and biopsy not preformed due to tumor location.

# Code 8 Clinical Diagnosis Only

### Assign code 8:

- Clinical diagnosis only, other than 5, 6 or 7
- The physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation (history and physical exam).
- The malignancy was reported by the physician in the medical record.
- If a physician treats a patient for cancer, in spite of a negative biopsy, this is a reportable clinical diagnosis.
- If a physician continues to describe a patient as having a reportable tumor, even after reviewing negative pathology results, this too is a reportable clinical diagnosis.

# Code 9 Unknown

### Assign code 9:

A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.

#### Example:

Patient presents at your facility for treatment for cancer and the records do not mention the method of confirmation.

# Hematopoietic or Lymphoid Tumors (M9590 – 9992)

# Hematopoietic or Lymphoid Tumors (M9590 – 9992)

- These instructions apply to "Codes for Hematopoietic and Lymphoid Neoplasms" <u>only</u>.
- There is **no** priority hierarchy for coding Diagnostic Confirmation for hematopoietic and lymphoid tumors.
- Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing.
- See the Hematopoietic Database (DB) for information on the definitive diagnostic confirmation for specific types of tumors.
- This data item <u>must be changed</u> if a more definitive method confirms the diagnosis <u>at any time during the course of the disease</u>.

# Code 1 Positive Histology

#### Assign code 1:

When the *microscopic* diagnosis is based on tissue specimens from:

- Biopsy
- Frozen section
- Surgery

- Autopsy
- D&C
- Bone marrow biopsy/aspiration

#### For leukemia only:

- Assign code 1 when the diagnosis is based on one of the methods listed above <u>or</u> :
- Complete blood count (CBC)
- White blood count (WBC)
- Peripheral blood smear (not the same as peripheral Flow Cytometry)
- Do not use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow, or blood.

# Code 2 Positive Cytology

### Assign code 2:

When the microscopic diagnosis is based on cytologic examination of cells such as:

- Sputum smears
- Bronchial brushings
- Bronchial washings
- Prostatic secretions
- Breast secretions
- Gastric fluid
- Spinal fluid

- Peritoneal fluid
- Pleural fluid
- Urinary sediment
- Cervical smears
- Vaginal smears
- Paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid

**IMPORTANT**: CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.

**NOTE:** These methods are rarely used for hematopoietic and lymphoid tumors.

## Code 3 Positive Histology & Positive Immunophenotyping and/or Positive Genetic Tests

### Assign code 3:

 When the diagnosis of cancer is based on any of the methods mentioned in Code 1 <u>and</u> positive immunophenotyping and/or positive genetic testing results which are diagnostic for that specific cancer.

### Example:

A bone marrow biopsy with a positive histology and a positive JAK2 test result.

Note: The immunophenotyping and/or genetic testing results must be positive.

# **Code 4** Positive microscopic confirmation, NOS

### Assign code 4:

Microscopic confirmation is all that is known.

• It is unknown if the cells were from histology or cytology.

#### **Example:**

The only information that you have is a report that states a pathology result but does not give the type of method or sample used and there are no op or procedure notes.

# Code 5 Positive Laboratory/Marker Tests

### Assign code 5:

 When the diagnosis of cancer is based on laboratory tests or <u>positive</u> immunophenotyping and/or <u>positive</u> genetic testing results which are clinically diagnostic for that specific cancer.

#### **IMPORTANT:**

Consult the Hematopoietic and Lymphoid Neoplasm Database for immunophenotyping and genetic tests.

## Code 6 Direct Visualization <u>without</u> Microscopic Confirmation

### Assign code 6:

- When there direct visualization without microscopic confirmation
- The tumor was visualized during a surgical or endoscopic procedure with no tissue resected for microscopic examination.
- Use this code when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy, or from gross autopsy findings in the absence of tissue or cytology findings.

# Code 7 Imaging Techniques without Microscopic Confirmation

### Assign Code 7:

The malignancy was reported by the physician from an imaging technique report only.

#### **Example:**

Scans revealed a mediastinal mass. Patient reported signs and symptoms consistent with lymphoma. Lab tests are inconclusive and biopsy not preformed due patients failing health and age.

# Code 8 Clinical Diagnosis Only

### Assign code 8:

- Clinical diagnosis only, other than 5, 6 or 7
- The physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation (history and physical exam).
- The malignancy was reported by the physician in the medical record.
- If a physician treats a patient for cancer, in spite of a negative biopsy, this is a reportable clinical diagnosis.
- If a physician continues to describe a patient as having a reportable tumor, even after reviewing negative pathology results, this too is a reportable clinical diagnosis.

# Code 9 Unknown

### Assign code 9:

A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.

#### Example:

Patient presents at your facility for treatment for cancer and the records do not mention the method of confirmation.

# Hematopoietic and Lymphoid Neoplasm Database

# Hematopoietic Project

## https://seer.cancer.gov/tools/heme/


- This site provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+. There are two tools for use with these rules:
- Hematopoietic & Lymphoid Neoplasm Database (Heme DB)
  - A tool to assist in screening for reportable cases and determining reportability requirements
  - The database contains abstracting and coding information for all hematopoietic and lymphoid neoplasm (9590/3-9992/3)
- Hematopoietic & Lymphoid Neoplasm Coding Manual
- Reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype
  - The introduction to the manual has an updated Steps in Priority Order for using the Hematopoietic and Lymphoid Neoplasm Coding Manual & Database.

### **Hematopoietic Project**

Updated January 22, 2019 (view Revision History)

Reporting Guidelines	<i>i</i> This manual and the corresponding database are to be used for coding cases d <b>The changes made do not require registrars to recode old cases.</b>	iagnosed January 1, 2010 and forward
Casefinding Lists	The changes made do not require registrars to recoue old cases.	
SEER Coding Manual + Hematopoietic Project -	This site provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+. There are two tools for use with these rules:	Support Resources
Hematopoietic and Lymphoid Database	<ol> <li>Hematopoietic &amp; Lymphoid Neoplasm Database (Heme DB)</li> <li>A tool to assist in screening for reportable cases and determining reportability requirements</li> <li>The database contains abstracting and coding information for all hematopoietic and lymphoid neoplasm (9590/3-9992/3)</li> </ol>	<ul> <li>Hematopoietic Conversion Documentation</li> <li>Comparison Documents</li> <li>Questions? Ask a SEER Registrar</li> <li>Join the SEER Registrar News listserv to receive announcements of upcoming changes.</li> </ul>
Comparison Documents Conversion Documentation		
Revision History	3. Hematopoietic & Lymphoid Neoplasm Coding Manual (PDF, 807 KB)	
Online Training	<ul> <li>Reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype</li> </ul>	
D-O-3 Coding Materials	b. The introduction to the manual has an updated Steps in Priority Order for using the Hematopoietic and Lymphoid Neoplasm Coding Manual & Database.	
2018 Solid Tumor Rules +		

### Hematopoietic and Lymphoid Neoplasm Database



### ALK-positive large B-cell lymphoma

Search Database ICD-O-3 Code Lists

Name

ALK-positive large B-cell lymphoma

ICD-O-3 Morphology Effective 2010 and later

9737/3: ALK-positive large B-cell lymphoma

Reportable

for cases diagnosed 2010 and later

Primary Site(s)

See Module 7

Most common sites of involvement: lymph nodes, mediastinal mass, nasopharynx, tongue, stomach, bone and soft tissues.

### Help me code for diagnosis year :

#### 2020

 $\sim$ 

#### Coding Manual: Hematopoietic Coding Manual (PDF)

#### Grade

Not Applicable

#### Module Rule

None

#### Alternate Names

ALK-positive LBCL

ALK-positive plasmablastic B-cell lymphoma [OBS]

Large B-cell lymphoma expressing the ALK kinase and lacking the t(2;5) translocation [OBS]

#### LBCL

#### Definition

ALK-positive large B-cell lymphoma (LBCL) is an aggressive neoplasm of ALK-positive monomorphic large immunoblast-like B cells, which usually have a plasma cell phenotype.

#### Abstractor Notes

(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9684/3.)

Most patients present with Stage III/IV. Because these tumors are negative for CD20 antigen, they are insensitive to rituximab.

#### **Definitive Diagnostic Methods**

Genetic testing Histologic confirmation Immunophenotyping Karyotyping

#### **Genetics Data**

CLTC-ALK fusion gene Immunoglobulin genes are clonally rearranged Phospho-STAT3 SQSTM1 or SEC31A fusion t(2;17)(p23;q23)

#### Immunophenotyping

ALK protein positive CD3-CD20-CD30-CD45 weak or negative CD79a-CD138+ CLTC-ALK fusion protein expression Cytoplasmic staining with other ALK translocations EMA IRF4/MUMI positive NPM1-ALK fusion protein with nucleolar ALK staining PAX5-PRDm1 (also known as BLIMP1) VS38+

#### Treatments

Chemotherapy

#### **Transformations to**

There are no known transformations

#### **Transformations from**

There are no known transformations

#### Same Primaries

9590/3 Malignant lymphoma, NOS 9591/3 Non-Hodgkin lymphoma, NOS 9679/3 Primary mediastinal (thymic) large B-cell lymphoma 9680/3 Diffuse large B-cell lymphoma, NOS 9684/3 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS 9835/3 Precursor cell lymphoblastic leukemia, NOS

#### **Corresponding ICD-9 Codes**

200.6 Anaplastic large cell lymphoma

#### Corresponding ICD-10 Codes

C83.3 Diffuse non-Hodgkins lymphoma, large cell (diffuse)

#### Corresponding ICD-10-CM Codes (U.S. only)

C83.3 Diffuse large b-cell lymphoma

(effective October 01, 2015)

#### Signs and Symptoms

Drenching night sweats Fatigue Fever (for no known reason) Mediastinal mass Pain in the chest, abdomen, or bones (for no known reason) Painless swelling in the lymph nodes Skin rash or itchy skin Weight loss (for no known reason)

#### **Diagnostic Exams**

Blood chemistry studies Bone marrow aspiration and biopsy CT (CAT) scan Complete blood count (CBC) Cytogenetic analysis Flow cytometry Immunohistochemistry Immunophenotyping Laparoscopy (rarely performed) Laparotomy (rarely performed) Lymph node biopsy MRI (magnetic resonance imaging) PET (positron emission tomography) scan Physical exam and history (H&P)

## **Progression and Transformation**

None

## **Epidemiology and Mortality**

Age: 36 years median age (9-70 years range)

Incidence: <1% of DLBCL lymphomas

Sex: male predominance

Survival: median survival 11 months; >156 months survival for children


# Diagnostic Confirmation Code Flow Sheets


# Diagnostic Confirmation Code Flow Sheet Solid Tumors (all tumors <u>except</u> 9590-9992)


#### Diagnostic Confirmation Code Flow Sheet Solid Tumors (all tumors <u>except</u> 9590-9992)


#### Description

- The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.
- Record the best mode of diagnostic confirmation recorded at any time in the patient's history of this cancer.
- The codes are in priority order.
- Code 1 has the highest priority.
- When presence of cancer is confirmed with multiple diagnostic methods, code the most definitive method used, if it is uncertain, code the procedure with the lower numeric value.












#### Diagnostic Confirmation Code Hematopoietic or Lymphoid Tumors (M9590-9992)


#### Description

- The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.
- Record the <u>best</u> mode of diagnostic confirmation recorded <u>at any time</u> in the patient's history of this cancer.
- There is <u>no priority hierarchy</u> for coding diagnostic confirmation for hematopoietic and lymphoid tumors.
- Code this field according the definitive diagnostic method used to confirm this malignancy.
- Definitive diagnostic methods are displayed in the hematopoietic database for each reportable hematopoietic and lymphoid neoplasm.
- Use code 3 whenever it applies-- i.e., whenever a positive histologic diagnosis is supported by a further positive test, such as IHC or genetic testing. \*Consult the Hematopoietic and Lymphoid Neoplasm Database for immunophenotyping and genetic tests.\*









# **QUESTIONS?**

Shelly Gray Quality Assurance Manage of Abstracting and Training Kentucky Cancer Registry 859-218-2101 sgray@kcr.uky.edu